Sunday, 19 August 2012

Tizanidine



Pronunciation: tye-ZAN-i-deen
Generic Name: Tizanidine
Brand Name: Zanaflex


Tizanidine is used for:

Treating muscle spasms. It may also be used for other conditions as determined by your doctor.


Tizanidine is a skeletal muscle relaxant. It works by blocking nerves that stimulate muscles to contract.


Do NOT use Tizanidine if:


  • you are allergic to any ingredient in Tizanidine

  • you are taking ciprofloxacin or fluvoxamine

Contact your doctor or health care provider right away if any of these apply to you.



Before using Tizanidine:


Some medical conditions may interact with Tizanidine. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have liver or kidney problems or prostate problems

Some MEDICINES MAY INTERACT with Tizanidine. Tell your health care provider if you are taking any other medicines, especially any of the following:


  • Acyclovir, antiarrhythmics (eg, amiodarone, mexiletine, propafenone), cimetidine, famotidine, fluvoxamine, hormonal contraceptives (eg, birth control pills), quinolone antibiotics (eg, ciprofloxacin), ticlopidine, verapamil, or zileuton because they may increase the risk of Tizanidine's side effects

This may not be a complete list of all interactions that may occur. Ask your health care provider if Tizanidine may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Tizanidine:


Use Tizanidine as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Take Tizanidine by mouth.

  • Food can change the way your body absorbs and uses Tizanidine. Be sure to discuss this with your doctor to determine the best way to take your dose, especially when changes to your dose are being considered, or if you are being prescribed a different dose form of Tizanidine (eg, tablets or capsules).

  • Do not suddenly stop taking Tizanidine. If you need to stop Tizanidine, your doctor will gradually lower your dose to prevent symptoms of withdrawal, including high blood pressure, fast heartbeat, tremor, anxiety, and muscle tension.

  • If you miss a dose of Tizanidine, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Tizanidine.



Important safety information:


  • Tizanidine may cause drowsiness, dizziness, lightheadedness, or fainting. These effects may be worse if you take it with alcohol or certain medicines. Use Tizanidine with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.

  • Do not drink alcohol or use medicines that may cause drowsiness (eg, sleep aids, muscle relaxers) while you are using Tizanidine; it may add to their effects. Ask your pharmacist if you have questions about which medicines may cause drowsiness.

  • Tizanidine may cause dizziness, lightheadedness, or fainting; alcohol, hot weather, exercise, or fever may increase these effects. To prevent them, sit up or stand slowly, especially in the morning. Sit or lie down at the first sign of any of these effects.

  • Do not switch between the tablet and capsule forms of Tizanidine unless your doctor tells you to. You may have an increased risk of side effects if you start to take one form and then switch to another. Check with your doctor or pharmacist before you take Tizanidine if you receive a different form than what you have previously been taking.

  • Tell your doctor or dentist that you take Tizanidine before you receive any medical or dental care, emergency care, or surgery.

  • Do not take more than the recommended dose or use for longer than prescribed without checking with your doctor.

  • Lab tests, such as liver tests, may be performed while you use Tizanidine. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.

  • Use Tizanidine with caution in the ELDERLY; they may be more sensitive to its effects.

  • Tizanidine should not be used in CHILDREN; safety and effectiveness in children have not been confirmed.

  • PREGNANCY and BREAST-FEEDING: It is not known if Tizanidine can cause harm to the fetus. If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Tizanidine while you are pregnant. It is not known if Tizanidine is found in breast milk. If you are or will be breast-feeding while you use Tizanidine, check with your doctor. Discuss any possible risks to your baby.


Possible side effects of Tizanidine:


All medicines may cause side effects, but many people have no, or minor side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Constipation; dizziness; drowsiness; dry mouth; flushing; tiredness; weakness.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); change in emotions, mood, or behavior; hallucinations; increased muscle spasms; muscle weakness; slow heartbeat; trouble urinating or lack of bladder control; urinary tract infection; yellowing of the skin or eyes.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Tizanidine side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (http://www.aapcc.org ), or emergency room immediately. Symptoms may include fainting; loss of consciousness; severe drowsiness; trouble breathing.


Proper storage of Tizanidine:

Store Tizanidine at 77 degrees F (25 degrees C). Brief storage at temperatures between 59 and 86 degrees F (15 and 30 degrees C) is permitted. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Tizanidine out of the reach of children and away from pets.


General information:


  • If you have any questions about Tizanidine, please talk with your doctor, pharmacist, or other health care provider.

  • Tizanidine is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Tizanidine. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Tizanidine resources


  • Tizanidine Side Effects (in more detail)
  • Tizanidine Dosage
  • Tizanidine Use in Pregnancy & Breastfeeding
  • Drug Images
  • Tizanidine Drug Interactions
  • Tizanidine Support Group
  • 73 Reviews for Tizanidine - Add your own review/rating


  • Tizanidine Prescribing Information (FDA)

  • Tizanidine Hydrochloride Monograph (AHFS DI)

  • Zanaflex Consumer Overview

  • Zanaflex Prescribing Information (FDA)

  • tizanidine Advanced Consumer (Micromedex) - Includes Dosage Information



Compare Tizanidine with other medications


  • Cluster Headaches
  • Muscle Spasm

Saturday, 18 August 2012

Cortizone-10 Anal Itch Cream cream, ointment, suppository


Generic Name: hydrocortisone rectal (cream, ointment, suppository) (hye dro KORT i zone REK tal)

Brand Names: Anucort-HC, Anumed-HC, Anusol-HC, Cortizone-10 Anal Itch Cream, Hemorrhoidal HC, Hemril-30, Hemril-HC Uniserts, Preparation H Hydrocortisone, Procto-Kit 1%, Procto-Kit 2.5%, Procto-Pak 1%, Proctocort, Proctocream-HC, Proctosert HC, Proctosol-HC, Proctozone HC, Proctozone-H, Recort Plus, Rectasol-HC, Tucks HC


What is hydrocortisone rectal?

Hydrocortisone is a steroid medicine that reduces inflammation in the body.


The information in this medication guide is specific to hydrocortisone rectal cream, ointment, or suppository.


Hydrocortisone rectal is used to treat itching or swelling caused by hemorrhoids or other inflammatory conditions of the rectum or anus.


Hydrocortisone rectal is also used together with other medications to treat ulcerative colitis, proctitis, and other inflammatory conditions of the lower intestines and rectal area.


Hydrocortisone rectal may also be used for purposes not listed in this medication guide.


What is the most important information I should know about hydrocortisone rectal?


The information in this medication guide is specific to hydrocortisone rectal cream, ointment, or suppository.


Do not take hydrocortisone rectal by mouth. It is for use only in your rectum.

This medication comes with patient instructions for safe and effective use. Follow these directions carefully. Ask your doctor or pharmacist if you have any questions. You may need to use this medication for up to 8 weeks.


Call your doctor at once if you have any bleeding from your rectum, feeling short of breath (even with mild exertion), swelling of your ankles or feet, or rapid weight gain.

There may be other drugs that can interact with hydrocortisone rectal. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.


Call your doctor if your symptoms do not improve or if they get worse after using this medicine for a few days.


What should I discuss with my health care provider before using hydrocortisone rectal?


Ask a doctor or pharmacist if it is safe for you to use this medicine if you have:



  • congestive heart failure;




  • a history of tuberculosis;




  • stomach ulcer or diverticulitis;




  • a colostomy or ileostomy;




  • fever or any type of infection;




  • kidney disease;




  • high blood pressure; or




  • myasthenia gravis.



Also tell your doctor if you have diabetes. Steroid medicines may increase the glucose (sugar) levels in your blood or urine. You may also need to adjust the dose of your diabetes medications.


FDA pregnancy category C. It is not known whether hydrocortisone rectal will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant while using this medication. It is not known whether hydrocortisone passes into breast milk or if it could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.

How should I use hydrocortisone rectal?


Use exactly as prescribed by your doctor. Do not use in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label.


Do not take hydrocortisone rectal by mouth. It is for use only in your rectum.

This medication comes with patient instructions for safe and effective use. Follow these directions carefully. Ask your doctor or pharmacist if you have any questions. You may need to use this medication for up to 8 weeks.


Wash your hands before and after using this medicine.

Try to empty your bowel and bladder just before using hydrocortisone rectal.


Remove the outer wrapper from the suppository before inserting it. Avoid handling the suppository too long or it will melt in your hands. The rectal suppository can stain clothing or other fabrics it comes into contact with.


For best results from the suppository, lie down after inserting it and hold in the suppository. The suppository will melt quickly once inserted and you should feel little or no discomfort while holding it in.


For best results from the cream, use only the applicator provided with the medication. Otherwise, follow the directions provided with your rectal cream.


Avoid using the bathroom for one to three hours after inserting the cream or suppository.

Apply the ointment to the rectum and surrounding skin of the rectal area as directed on the package label.


Call your doctor if your symptoms do not improve or if they get worse after using this medicine for a few days.


Store the rectal cream at room temperature away from moisture and heat. Store the rectal suppositories at cool room temperature away from moisture and heat. Do not refrigerate or freeze them.

What happens if I miss a dose?


Use the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not use extra medicine to make up the missed dose.


What happens if I overdose?


Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

An overdose of hydrocortisone rectal is not expected to produce life-threatening symptoms. However, long-term use of high steroid doses can lead to symptoms such as thinning skin, easy bruising, changes in the shape or location of body fat (especially in your face, neck, back, and waist), increased acne or facial hair, menstrual problems, impotence, or loss of interest in sex.


What should I avoid while using hydrocortisone rectal ?


Avoid getting a vaccine during your treatment with hydrocortisone rectal. Vaccines may not work as well while you are using a steroid medicine.


Hydrocortisone rectal side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Call your doctor at once if you have a serious side effect such as:

  • feeling short of breath, even with mild exertion;




  • swelling of your ankles or feet;




  • muscle weakness;




  • rapid weight gain, especially in your face and midsection;




  • severe rectal pain or burning;




  • bleeding from your rectum;




  • severe stomach pain;




  • sudden and severe headache or pain behind your eyes; or




  • seizure (convulsions).



Less serious side effects may include:



  • mild rectal pain or burning;




  • acne;




  • changes in your menstrual periods;




  • increased sweating; or




  • increased facial or body hair growth.



This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs will affect hydrocortisone rectal ?


Before using hydrocortisone rectal, tell your doctor if you also use insulin or take oral diabetes medication.


There may be other drugs that can interact with hydrocortisone rectal. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.



More Cortizone-10 Anal Itch Cream resources


  • Cortizone-10 Anal Itch Cream Side Effects (in more detail)
  • Cortizone-10 Anal Itch Cream Use in Pregnancy & Breastfeeding
  • Cortizone-10 Anal Itch Cream Drug Interactions
  • 0 Reviews for Cortizone-10 Anal Itch - Add your own review/rating


Compare Cortizone-10 Anal Itch Cream with other medications


  • Anal Itching
  • Aphthous Stomatitis, Recurrent
  • Atopic Dermatitis
  • Dermatitis
  • Eczema
  • Gingivitis
  • Proctitis
  • Pruritus
  • Psoriasis
  • Seborrheic Dermatitis
  • Skin Rash


Where can I get more information?


  • Your pharmacist can provide more information about hydrocortisone rectal cream, ointment, or suppository.

See also: Cortizone-10 Anal Itch side effects (in more detail)


Friday, 17 August 2012

Acidex, Compound Alginate Oral Suspension, Heartburn and Indigestion Liquid





1. Name Of The Medicinal Product



Acidex, Compound Alginate Oral Suspension, Heartburn and Indigestion Liquid



Compound Alginate, Oral Suspension, Heartburn and Indigestion Liquid



Brunel Healthcare Heartburn and Indigestion Liquid



Superdrug Acid Indigestion and Heartburn Relief Liquid



Heartburn and Indigestion Relief



SETLERS Heartburn and Indigestion Liquid



Coalgicarb Suspension



Lloydspharmacy Heartburn and Indigestion Liquid



Raft-Eze Liquid



Boots Heartburn Relief Aniseed Flavour



Co-op Heartburn and Indigestion Liquid



Entrocalm Heartburn and Indigestion Relief



Morrisons Heartburn and Indigestion Liquid



Peptac Liquid (Ivax Pharmaceuticals UK)



Asda Heartburn and Indigestion Liquid



Numark Heartburn and Indigestion Liquid



Wilkinson Heartburn and Indigestion Liquid



Sainsbury's Heartburn and Indigestion Liquid


2. Qualitative And Quantitative Composition



Each 5 ml contains:









Sodium Bicarbonate BP

133.5 mg

Sodium Alginate BP

250 mg

Calcium Carbonate BP

80 mg


3. Pharmaceutical Form



Aniseed Flavoured Pink Suspension



4. Clinical Particulars



4.1 Therapeutic Indications



Acidex Compound Alginate Oral Suspension Heartburn and Indigestion Liquid alleviates the painful conditions resulting from the reflux of gastric acid and bile into the oesophagus by suppressing the reflux itself. It is indicated in heartburn, including heartburn of pregnancy, dyspepsia associated with gastric reflux, hiatus hernia, reflux oesophagitis, regurgitation and all cases of epigastric and retrosternal distress where the underlying cause is gastric reflux.



4.2 Posology And Method Of Administration



For oral use







Adults and children over 12 years:

Two to four 5 ml spoonfuls.

Children 6 - 12 years:

One to two 5 ml spoonfuls


Not recommended in children under six years of age.



Doses should be taken after meals and at bedtime.



4.3 Contraindications



There are no specific contraindications.



4.4 Special Warnings And Precautions For Use



1. Each 10 ml dose of Acidex Compound Alginate Oral Suspension Heartburn and Indigestion Liquid contains about 6 mmoles of sodium and therefore care should be exercised in patients on a sodium restricted diet.



2. Acidex Compound Alginate Oral Suspension Heartburn and Indigestion Liquid should not be taken within 1 to 2 hours of taking other medicines by mouth, or for more than 2 weeks if symptoms persist.



3. Acidex Compound Alginate Oral Suspension Heartburn and Indigestion Liquid should not be used by patients allergic to any of its constituents.



4. Parahydroxybenzoates (E214 and E216): may cause allergic reactions (possibly delayed).



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



1. Antacids may interact with other drugs as they alter the gastric pH which may affect dissolution, solubility or ionization of the other drug. Antacids reduce the absorption of certain drugs from the following groups: ACE Inhibitors, Analgesics, Antibacterials, Antiepileptics, Antifungals, Antimalarials, Antipsychotics, Bisphosphonates, Penicillamine.



2. Antacids may increase the pH of the urine and affect the rate of drug elimination. Excretion of basic drugs is decreased whereas acidic drugs are eliminated more rapidly.



3. Due to effects at the renal level sodium bicarbonate may reduce plasma lithium levels and increase plasma quinidine levels.



4.6 Pregnancy And Lactation



Acidex Compound Alginate Oral Suspension Heartburn and Indigestion Liquid is indicated for heartburn of pregnancy and may be used during lactation.



For Acidex Compound Alginate Oral Suspension Heartburn and Indigestion Liquid no clinical data on exposed pregnancies are available. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development. To date, no other relevant epidemiological data are available.



Caution should be exercised when prescribing to pregnant women.



4.7 Effects On Ability To Drive And Use Machines



There are no effects on ability to drive or operate machinery.



4.8 Undesirable Effects



Constipation, flatulence, stomach cramps or belching may occasionally occur.



4.9 Overdose



As Acidex Compound Alginate Oral Suspension Heartburn and Indigestion Liquid's mode of action is physical, overdosage in terms of the alginate content is virtually no hazard. The only consequence is abdominal distension which is best treated conservatively. The relatively low concentrations of sodium and calcium carbonate in Acidex Compound Alginate Oral Suspension Heartburn and Indigestion Liquid would also make serious consequences from overdosage very unlikely.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



When taken after a meal Sodium Alginate forms a rigid raft of alginic acid in the stomach reducing gastric reflux. This raft formed is maintained in the stomach for two hours. Sodium bicarbonate reacts with gastric acid to produce carbon dioxide which is retained in the gel and allows the raft to rise to the surface of the gastric contents. Calcium ions from calcium carbonate link the alginic acid molecules and strengthen the raft.



5.2 Pharmacokinetic Properties



Alginic acid is not absorbed into the systemic circulation.



5.3 Preclinical Safety Data



There is no Preclinical Safety Data.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Carbomer (Carbopol 974P)



Sodium Hydroxide



Saccharin Sodium



Ethyl parahydroxybenzoate (E214)



Propyl parahydroxybenzoate (E216)



Butyl parahydroxybenzoate



Isopropyl Alcohol



Erythrosine Colour (E127)



Aniseed Oil



Purified Water



6.2 Incompatibilities



None known.



6.3 Shelf Life



24 months - amber glass bottles



18 months - HDPE bottles



15 months – PET bottles



6.4 Special Precautions For Storage



Do not store above 25ÂșC. Do not refrigerate.



6.5 Nature And Contents Of Container



Pharmaceutical Grade III amber glass bottles with pilfer proof caps.



High density polyethylene bottles with tamper evident screw caps.



PET bottle with tamper evident screw caps.



Pack sizes: 50ml, 100ml, 150ml, 200ml, 250ml, 300ml and 500ml.



50ml (PET)



6.6 Special Precautions For Disposal And Other Handling



Not applicable.



7. Marketing Authorisation Holder



Pinewood Laboratories Limited,



Ballymacarbry,



Clonmel,



Co. Tipperary.



8. Marketing Authorisation Number(S)



PL 4917/0021



9. Date Of First Authorisation/Renewal Of The Authorisation



25/03/1998



10. Date Of Revision Of The Text



19/04/2011




Thursday, 16 August 2012

Hydrocortisone/Diphenhydramine Spray


Pronunciation: HYE-droe-KOR-ti-sone/DYE-fen-HYE-dra-meen
Generic Name: Hydrocortisone/Diphenhydramine
Brand Name: HC DermaPax


Hydrocortisone/Diphenhydramine Spray is used for:

Treating inflammation and itching caused by minor skin irritations (eg, poison ivy, poison oak, insect bites). It may also be used for other conditions as determined by your doctor.


Hydrocortisone/Diphenhydramine Spray contains a topical corticosteroid and an antihistamine. The corticosteroid works by reducing skin inflammation (redness, swelling, itching, and irritation). The antihistamine works by blocking the action of histamine, which reduces the symptoms of an allergic reaction.


Do NOT use Hydrocortisone/Diphenhydramine Spray if:


  • you are allergic to any ingredient in Hydrocortisone/Diphenhydramine Spray

Contact your doctor or health care provider right away if this applies to you.



Before using Hydrocortisone/Diphenhydramine Spray:


Some medical conditions may interact with Hydrocortisone/Diphenhydramine Spray. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have any kind of skin infection, cuts, scrapes, sunburn, or lessened blood flow to your skin

  • if you have had a recent vaccination; have measles, tuberculosis (TB), chickenpox, or shingles; or have had a positive TB test

  • if you have a history of the blood disease porphyria

  • if you are taking prednisone or similar medicines

Some MEDICINES MAY INTERACT with Hydrocortisone/Diphenhydramine Spray. However, no specific interactions with Hydrocortisone/Diphenhydramine Spray are known at this time.


Ask your health care provider if Hydrocortisone/Diphenhydramine Spray may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Hydrocortisone/Diphenhydramine Spray:


Use Hydrocortisone/Diphenhydramine Spray as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Apply a small amount of medicine to the affected area as directed by your doctor or on the package labeling.

  • Wash your hands after you apply Hydrocortisone/Diphenhydramine Spray, unless your hands are part of the treated area.

  • Do not bandage or cover the treated skin area unless directed by your doctor.

  • If you miss a dose of Hydrocortisone/Diphenhydramine Spray and you are using it regularly, apply it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not apply 2 doses at once.

Ask your health care provider any questions you may have about how to use Hydrocortisone/Diphenhydramine Spray.



Important safety information:


  • Hydrocortisone/Diphenhydramine Spray is for external use only. Do not get Hydrocortisone/Diphenhydramine Spray in your eyes, nose, or mouth. If you get it in any of these areas, rinse right away with cool water.

  • Do not use Hydrocortisone/Diphenhydramine Spray on the face, in the groin area, or under the armpits. Do not use Hydrocortisone/Diphenhydramine Spray to treat diaper rash.

  • Do not use more than the recommended dose or use for longer than 7 days without checking with your doctor.

  • If your symptoms do not get better within 7 days, if they get worse, or if they clear up and then come back, check with your doctor.

  • Check with your doctor before you have any vaccines while you are using Hydrocortisone/Diphenhydramine Spray.

  • Do not use Hydrocortisone/Diphenhydramine Spray for other skin conditions at a later time.

  • Do not use other medicines or products on your skin without first checking with your doctor.

  • Overuse of topical products may worsen your condition.

  • Hydrocortisone/Diphenhydramine Spray has hydrocortisone and diphenhydramine in it. Before you start any new prescription or nonprescription medicine, check the label to see if it has hydrocortisone or diphenhydramine in it too. If it does or if you are not sure, check with your doctor or pharmacist.

  • Tell your doctor or dentist that you take Hydrocortisone/Diphenhydramine Spray before you receive any medical or dental care, emergency care, or surgery.

  • Serious side effects may occur if too much of Hydrocortisone/Diphenhydramine Spray is absorbed through the skin. This may be more likely to occur if you use Hydrocortisone/Diphenhydramine Spray over a large area of the body. It may also be more likely if you wrap or bandage the area after you apply Hydrocortisone/Diphenhydramine Spray. The risk is greater in children. Do not use more than the recommended dose. Contact your doctor right away if you develop unusual weight gain (especially in the face), muscle weakness, increased thirst or urination, confusion, unusual drowsiness, severe or persistent headache, or vision changes. Discuss any questions or concerns with your doctor.

  • Corticosteroids may affect growth rate in CHILDREN and teenagers in some cases. They may need regular growth checks while they use Hydrocortisone/Diphenhydramine Spray.

  • Hydrocortisone/Diphenhydramine Spray should not be used in CHILDREN younger than 2 years old without first checking with the child's doctor; safety and effectiveness in these children have not been confirmed.

  • PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Hydrocortisone/Diphenhydramine Spray while you are pregnant. It is not known if Hydrocortisone/Diphenhydramine Spray is found in breast milk after topical use. If you are or will be breast-feeding while you use Hydrocortisone/Diphenhydramine Spray, check with your doctor. Discuss any possible risks to your baby.


Possible side effects of Hydrocortisone/Diphenhydramine Spray:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Dryness; mild stinging, burning, or itching.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); acne-like rash; burning, cracking, irritation, or peeling not present before you began using Hydrocortisone/Diphenhydramine Spray; excessive hair growth; inflamed hair follicles; inflammation around the mouth; thinning, softening, or discoloration of the skin.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.



If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include increased thirst or urination; muscle weakness; unusual weight gain, especially in the face.


Proper storage of Hydrocortisone/Diphenhydramine Spray:

Store Hydrocortisone/Diphenhydramine Spray at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not freeze. Do not store in the bathroom. Keep Hydrocortisone/Diphenhydramine Spray out of the reach of children and away from pets.


General information:


  • If you have any questions about Hydrocortisone/Diphenhydramine Spray, please talk with your doctor, pharmacist, or other health care provider.

  • Hydrocortisone/Diphenhydramine Spray is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Hydrocortisone/Diphenhydramine Spray. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Hydrocortisone/Diphenhydramine resources


  • Hydrocortisone/Diphenhydramine Use in Pregnancy & Breastfeeding
  • Hydrocortisone/Diphenhydramine Drug Interactions
  • Hydrocortisone/Diphenhydramine Support Group
  • 0 Reviews for Hydrocortisone/Diphenhydramine - Add your own review/rating


Compare Hydrocortisone/Diphenhydramine with other medications


  • Pruritus

Lactugal





1. Name Of The Medicinal Product



Lactugal.


2. Qualitative And Quantitative Composition



Active Ingredient:



Lactulose Solution BP 99.897 % v/v



(Equivalent to 62.0-74.0% w/v of Lactulose).



3. Pharmaceutical Form



Oral solution. Banana Flavour



4. Clinical Particulars



4.1 Therapeutic Indications



Constipation; Hepatic encephalopathy (Portal systemic encephalopathy).



4.2 Posology And Method Of Administration



For oral administration.



Adults:



Constipation: 15ml once or twice daily.



Hepatic Encephalopathy: Initially 30-50ml three times daily, adjust dose to produce 2 or 3 soft stools daily.



Children:



1-5 years: 5ml twice daily.



5-10 years: l0ml twice daily.



Elderly:



The normal adult dosage is appropriate.



4.3 Contraindications



Lactugal is contra-indicated where there is evidence of gastro-intestinal obstruction and to patients with galactosaemia.



4.4 Special Warnings And Precautions For Use



There are no warnings or precautions for patients with any impaired organ function.



Lactulose should be used with caution in patients exhibiting lactose intolerance.



Due to the product's physiological mode of action it may take up to 48 hours before effects are obtained, however, the product does exhibit a 'carry over' effect which may enable the patient to reduce the dose gradually over a period of time.



Lactulose solution has a calorific value of approximately 19Kcals/5mI. As, however, only negligible amounts of lactulose are absorbed from the gastrointestinal tract the available calories will be much lower than this, and therefore, is unlikely to adversely affect diabetes.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



There are no known interactions with lactulose.



4.6 Pregnancy And Lactation



Wide clinical experience in combination with data from animal production studies has not revealed any embryotoxic hazards to the foetus if used in the recommended dosage during pregnancy. If drug therapy is required during pregnancy or for lactating mothers, the use of this drug is acceptable.



4.7 Effects On Ability To Drive And Use Machines



There is no evidence to show that lactulose affects driving ability.



4.8 Undesirable Effects



A normal dosage of lactulose may cause mild abdominal pain and flatulence which will disappear spontaneously after a few days. High doses may provoke nausea in some patients and this can be minimised by administration with water, fruit juice or meals.



4.9 Overdose



If clinically important electrolyte disturbances occur, suitable corrective measures should be taken.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Lactulose is a synthetic disaccharide which is metabolised by gastro-intestinal bacterial flora to low molecular weight acids (chiefly lactic and acetic acids). There is no endogenous metabolising enzyme in the human gut.



Its mode of action in constipation is as an osmotic agent producing soft stools.



A dual mode of action is proposed for the efficacy of lactulose in Portal System Encephalopathy, relating to the metabolism of ammonia and subsequent nitrogenous toxins. The reduction in gastro-intestinal pH results in a net entrapment of ammonia in the gut lumen. Lactulose has also been shown to alter ammonia metabolism by microbial flora.



5.2 Pharmacokinetic Properties



Lactulose is absorbed from the gastro-intestinal tract to 0.4 - 2% and is excreted unchanged with the urine. There are no human lactulose disaccharide enzymes; metabolism of lactulose to lactic acid occurs via gastro-intestinal microbial flora only. Due to its poor bioavailability, plasma lactulose concentrations are negligible.



There are no known changes in kinetic properties in patients with organic diseases which may alter drug disposition.



5.3 Preclinical Safety Data



None stated.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Banana Flavour Quinoline Yellow



(17.41.0042) (E 1 04)



6.2 Incompatibilities



There are no known incompatibilities.



6.3 Shelf Life



36 months from the date of manufacture.



6.4 Special Precautions For Storage



Store at a temperature not exceeding 20°C. Do not freeze



6.5 Nature And Contents Of Container



Amber glass winchesters with polypropylene caps as closures. Polyethylene containers with polypropylene caps as closures.



6.6 Special Precautions For Disposal And Other Handling



There are no special storage or handling instructions for this product.



Administrative Data



7. Marketing Authorisation Holder



Intrapharm Laboratories Ltd



Maidstone



Kent



ME15 9QS



United Kingdom



8. Marketing Authorisation Number(S)



PL 17509/0011



9. Date Of First Authorisation/Renewal Of The Authorisation



4 September 2003



10. Date Of Revision Of The Text




Wednesday, 15 August 2012

Fosinopril and Hydrochlorothiazide





Dosage Form: tablet
Fosinopril Sodium and Hydrochlorothiazide Tablets

USE IN PREGNANCY


When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus. When pregnancy is detected, fosinopril sodium and hydrochlorothiazide should be discontinued as soon as possible. See WARNINGS, Fetal/Neonatal Morbidity and Mortality.



Fosinopril and Hydrochlorothiazide Description

Fosinopril sodium is a white to off-white crystalline powder, soluble (>100 mg/mL) in water, in ethanol and in methanol, and slightly soluble in hexane. Fosinopril sodium is designated chemically as L-proline, 4-cyclohexyl-1-[[[2-methyl-1-(1-oxopropoxy)- propoxy](4-phenylbutyl)phosphinyl]acetyl]-, sodium salt, trans-; its structural formula is:



Its empirical formula is C30H45NNaO7P, and its molecular weight is 585.65.


Fosinoprilat, the active metabolite of fosinopril, is a non-sulfhydryl angiotensin-converting enzyme inhibitor. Fosinopril is converted to fosinoprilat by hepatic cleavage of the ester group.


Hydrochlorothiazide, USP is a white, or practically white, practically odorless, crystalline powder. It is slightly soluble in water; freely soluble in sodium hydroxide solution, in n-butylamine, and in dimethylformamide; sparingly soluble in methanol; and insoluble in ether, in chloroform, and in dilute mineral acids. Hydrochlorothiazide is designated chemically as 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; its structural formula is:



Its empirical formula is C7H8ClN3O4S2 and its molecular weight is 297.73. Hydrochlorothiazide is a thiazide diuretic.


Fosinopril sodium and hydrochlorothiazide tablets are a combination of fosinopril sodium and hydrochlorothiazide, USP. It is available for oral use in two tablet strengths: fosinopril sodium and hydrochlorothiazide tablets 10/12.5, containing 10 mg of fosinopril sodium and 12.5 mg of hydrochlorothiazide, USP; and fosinopril sodium-hydrochlorothiazide tablets 20/12.5, containing 20 mg of fosinopril sodium and 12.5 mg of hydrochlorothiazide, USP. The inactive ingredients of the tablets include carnauba wax, crospovidone, lactose anhydrous, lactose monohydrate, starch, red iron oxide and zinc stearate.



Fosinopril and Hydrochlorothiazide - Clinical Pharmacology



Mechanism of Action


Fosinopril and fosinoprilat inhibit angiotensin-converting enzyme (ACE) in human subjects and in animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. Inhibition of ACE results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to decreased aldosterone secretion. The latter decrease may result in a small increase of serum potassium. Hypertensive patients treated with fosinopril alone for an average of 8 weeks had elevations of serum potassium of approximately 0.1 mEq/L. Similar patients treated with hydrochlorothiazide alone had a mean reduction in serum potassium of 0.15 mEq/L, while patients who received combined treatment with 10/12.5 mg or 20/12.5 mg of Fosinopril and Hydrochlorothiazide had reductions of 0.07 mEq/L and 0.03 mEq/L, respectively. (See PRECAUTIONS.)


Removal of angiotensin II negative feedback on renin secretion leads to increased plasma renin activity.


ACE is identical to kininase, an enzyme that degrades bradykinin. Whether increased levels of bradykinin, a potent vasodepressor peptide, play a role in the therapeutic effects of fosinopril sodium and hydrochlorothiazide tablets remains to be elucidated.


While the mechanism through which fosinopril lowers blood pressure is believed to be primarily suppression of the renin-angiotensin-aldosterone system, fosinopril has an antihypertensive effect even in patients with low-renin hypertension.


Hydrochlorothiazide is a thiazide diuretic. Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts. Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium. The renin-aldosterone link is mediated by angiotensin, so coadministration of an ACE inhibitor tends to reverse the potassium loss associated with these diuretics.


The mechanism of the antihypertensive effect of thiazides is unknown.



Pharmacokinetics and Metabolism


The absolute absorption of fosinopril averages 36% of an oral dose. The primary site of absorption is the proximal small intestine. While the rate of absorption may be slowed by the presence of food in the gastrointestinal tract, the extent of absorption of fosinopril is essentially unaffected.


Following oral administration of hydrochlorothiazide, peak plasma concentrations are achieved in 1 to 2.5 hours, and the extent of absorption is 50% to 80%. The reported studies of food effects on hydrochlorothiazide absorption have been inconclusive. The absorption of hydrochlorothiazide is increased by agents that reduce gastrointestinal motility. It is reported to be decreased by 50% in patients with congestive heart failure.


Cleavage of the ester group (primarily in the liver) converts fosinopril to its active metabolite, fosinoprilat. The time to peak plasma concentrations of fosinoprilat is about 3 hours, independent of the administered dose of fosinopril. In patients with hepatic dysfunction due to cirrhosis, conversion of fosinopril to fosinoprilat may be slowed, but the extent of this conversion is unchanged.


Fosinoprilat is highly protein bound (95%), but has negligible binding to cellular components of blood. The peak serum concentration and the area under the concentration-time curve of fosinoprilat is directly proportional to the administered dose of fosinopril.


After an oral dose of radio-labeled fosinopril, 75% of radioactivity in plasma was present as active fosinoprilat, 20% to 30% as a glucuronide conjugate of fosinoprilat, and 1% to 5% as a p-hydroxy metabolite of fosinoprilat. Since fosinoprilat is not biotransformed after intravenous administration, fosinopril, not fosinoprilat, appears to be the precursor for the glucuronide and p-hydroxy metabolites. In rats, the p-hydroxy metabolite of fosinoprilat is as potent an inhibitor of ACE as fosinoprilat; the glucuronide conjugate is devoid of ACE inhibitory activity.


Studies in animals indicate that fosinopril and fosinoprilat do not cross the blood-brain barrier, but fosinoprilat does cross the placenta of pregnant animals. In humans, hydrochlorothiazide crosses the placenta freely, and levels in umbilical-cord blood are similar to those in the maternal circulation.


Hydrochlorothiazide is not metabolized. Its apparent volume of distribution is 3.6 L/kg to 7.8 L/kg, and its measured plasma protein binding is 67.9%. The drug also accumulates in red blood cells, so that whole blood levels are 1.6 to 1.8 times those measured in plasma.


After intravenous administration, fosinoprilat is eliminated approximately equally by the liver and kidney. After oral administration of radio-labeled fosinopril, approximately half of the absorbed dose is excreted in the urine and the remainder is excreted in the feces. In two studies involving healthy subjects, the mean body clearance of intravenous fosinoprilat was between 26 mL/min and 39 mL/min.


In hypertensive patients with normal renal and hepatic function, the effective half-life of accumulation of fosinoprilat following multiple dosing of fosinopril sodium is 11.5 hours. Thus, steady-state concentrations of fosinoprilat should be reached after 2 or 3 doses of fosinopril sodium and hydrochlorothiazide given once daily.


In patients with renal insufficiency (creatinine clearance <80 mL/min/1.73m2), the total body clearance of fosinoprilat is approximately one half of that in patients with normal renal function, while absorption, bioavailability, and protein binding are not appreciably altered. The clearance of fosinoprilat does not differ appreciably with the degree of renal insufficiency, because the diminished renal elimination is offset by increased hepatobiliary elimination. A modest increase in plasma AUC levels (less than two times that in normals) was observed in patients with various degrees of renal insufficiency, including end-stage renal failure (creatinine clearance <10 mL/min/1.73m2) (see DOSAGE AND ADMINISTRATION).


Fosinopril is not well dialyzed. Clearance of fosinoprilat by hemodialysis and peritoneal dialysis averages 2% and 7%, respectively, of urea clearances.


In patients with hepatic insufficiency (alcoholic or biliary cirrhosis), the apparent total body clearance of fosinoprilat is approximately one half of that in patients with normal hepatic function.


In elderly (male) subjects (65 to 74 years old) with clinically normal renal and hepatic function, there appear to be no significant differences in pharmacokinetic parameters for fosinoprilat compared to those of younger subjects (20 to 35 years old).


Thiazide diuretics are eliminated by the kidney, with a terminal half-life of 5 to 15 hours. In a study of patients with impaired renal function (mean creatinine clearance of 19 mL/min), the half-life of hydrochlorothiazide elimination was lengthened to 21 hours.


When Fosinopril and Hydrochlorothiazide are administered concomitantly, the pharmacokinetics of hydrochlorothiazide are essentially unaffected. Serum levels of fosinoprilat are increased after several weeks of coadministration of hydrochlorothiazide and fosinopril, but the increase is not sufficient to warrant any change in dosing.



Pharmacodynamics


After single doses of 10 mg to 40 mg of fosinopril, serum ACE activity was inhibited by at least 90% from 2 to 12 hours after dosing. At 24 hours, serum ACE activity remains suppressed by 85% to 93%.


Administration of fosinopril to patients with mild to moderate hypertension results in a reduction of both supine and standing blood pressure to about the same extent with no compensatory tachycardia. In studies in hypertensive patients after three months of fosinopril monotherapy, hemodynamic responses to various stimuli (isometric exercise, 45° head-up tilt, mental challenges) were unchanged compared to baseline, suggesting that fosinopril did not affect the activity of the sympathetic nervous system. Instead, fosinopril-induced reduction in blood pressure appears to be mediated by a reduction in peripheral vascular resistance without reflex cardiac effects. In similar studies, renal, splanchnic, cerebral, and skeletal-muscle blood flows were all unchanged compared to baseline, as was glomerular filtration rate. Symptomatic postural hypotension is infrequent, although it can occur in patients who are salt- and/or volume-depleted (see WARNINGS).


Following oral administration of single doses of 10 mg to 40 mg, fosinopril lowered blood pressure within one hour, with peak reductions achieved 2 to 6 hours after dosing. The antihypertensive effect of a single dose persisted for 24 hours. Following four weeks of monotherapy in placebo-controlled trials in patients with mild to moderate hypertension, once-daily doses of 20 mg to 80 mg lowered supine or seated blood pressures (systolic/diastolic) 24 hours after dosing by an average of 8 to 9 / 6 to 7 mmHg more than placebo. The trough effect was about 50% to 60% of the peak diastolic response and about 80% of the peak systolic response.


In clinical studies of various combinations that included 0 mg to 40 mg of fosinopril and 0 mg to 37.5 mg of hydrochlorothiazide, the antihypertensive effects were increased with increasing dose of either component. Peak blood pressure reductions were achieved 2 to 6 hours after dosing. The mean reductions in seated blood pressure (systolic/diastolic) associated with fosinopril sodium and hydrochlorothiazide 10/12.5 after 24 hours were 9 to 18/5 to 7 mmHg greater than those associated with placebo; those associated with fosinopril sodium and hydrochlorothiazide 20/12.5 after 24 hours were 12 to 17/8 to 10 mmHg greater than those associated with placebo. These trough effects were 60% to 90% of the corresponding peak effects.


Although hydrochlorothiazide tends to be more effective in low-renin hypertensive patients (mainly blacks), and fosinopril-like other ACE inhibitors-tends to be more effective in high-renin patients (mainly non-blacks), the effectiveness of fosinopril sodium and hydrochlorothiazide is independent of race, age, and gender.



Indications and Usage for Fosinopril and Hydrochlorothiazide


Fosinopril sodium and hydrochlorothiazide tablets are indicated for the treatment of hypertension.


These fixed dose combinations are not indicated for initial therapy (see DOSAGE AND ADMINISTRATION).


In using fosinopril sodium and hydrochlorothiazide tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that fosinopril does not have a similar risk (see WARNINGS,Neutropenia/Agranulocytosis).


ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS, Head and Neck Angioedema and Intestinal Angioedema).



Contraindications


Fosinopril sodium and hydrochlorothiazide is contraindicated in patients who are anuric. Fosinopril sodium and hydrochlorothiazide is also contraindicated in patients who are hypersensitive to fosinopril, to any other ACE inhibitor, to hydrochlorothiazide, or other sulfonamide-derived drugs, or any other ingredient or component in the formulation. Hypersensitivity reactions are more likely to occur in patients with a history of allergy or bronchial asthma.



Warnings



Anaphylactoid and Possibly Related Reactions


Presumably because angiotensin-converting enzyme inhibitors affect the metabolism of eicosanoids and polypeptides, including endogenous bradykinin, patients receiving ACE inhibitors (including fosinopril sodium and hydrochlorothiazide) may be subject to a variety of adverse reactions, some of them serious.


Head and Neck Angioedema

 Angioedema of the face, extremities, lips, tongue, glottis and larynx has been reported in patients treated with angiotensin-converting enzyme inhibitors. Angioedema associated with laryngeal edema can be fatal. If laryngeal stridor or angioedema of the face, tongue, or glottis occurs, treatment with fosinopril sodium and hydrochlorothiazide should be discontinued and appropriate therapy instituted immediately. When involvement of the tongue, glottis, or larynx appears likely to cause airway obstruction, appropriate therapy, e.g., subcutaneous epinephrine injection 1:1000 (0.3 mL to 0.5 mL) should be promptly administered (see PRECAUTIONSand ADVERSE REACTIONS).


Intestinal Angioedema

 Intestinal angioedema has been reported in patients treated with ACE inhibitors. These patients presented with abdominal pain (with or without nausea or vomiting); in some cases there was no prior history of facial angioedema and C-1 esterase levels were normal. The angioedema was diagnosed by procedures including abdominal CT scan or ultrasound, or at surgery, and symptoms resolved after stopping the ACE inhibitor. Intestinal angioedema should be included in the differential diagnosis of patients on ACE inhibitors presenting with abdominal pain.


Anaphylactoid Reactions During Desensitization

 Two patients undergoing desensitizing treatment with hymenoptera venom while receiving ACE inhibitors sustained life-threatening anaphylactoid reactions. In the same patients, these reactions were avoided when ACE inhibitors were temporarily withheld, but they reappeared upon inadvertent rechallenge.


Anaphylactoid Reactions During Membrane Exposure

 Anaphylactoid reactions have been reported in patients dialyzed with high-flux membranes and treated concomitantly with an ACE inhibitor. Anaphylactoid reactions have also been reported in patients undergoing low-density lipoprotein apheresis with dextran sulfate absorption.



Hypotension


Fosinopril sodium and hydrochlorothiazide can cause symptomatic hypotension. Like other ACE inhibitors, fosinopril has been only rarely associated with hypotension in uncomplicated hypertensive patients. Symptomatic hypotension is most likely to occur in patients who have been volume- and/or salt-depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. Volume and/or salt depletion should be corrected before initiating therapy with fosinopril sodium and hydrochlorothiazide.


Fosinopril sodium and hydrochlorothiazide should be used cautiously in patients receiving concomitant therapy with other antihypertensives. The thiazide component of fosinopril sodium and hydrochlorothiazide may potentiate the action of other antihypertensive drugs, especially ganglionic or peripheral adrenergic-blocking drugs. The antihypertensive effects of the thiazide component may also be enhanced in the post-sympathectomy patient.


In patients with congestive heart failure, with or without associated renal insufficiency, ACE inhibitor therapy may cause excessive hypotension, which may be associated with oliguria, azotemia, and (rarely) with acute renal failure and death. In such patients, fosinopril sodium and hydrochlorothiazide therapy should be started under close medical supervision; they should be followed closely for the first 2 weeks of treatment and whenever the dose of fosinopril or diuretic is increased.


If hypotension occurs, the patient should be placed in a supine position and, if necessary, treated with intravenous infusion of physiological saline. Fosinopril sodium and hydrochlorothiazide treatment usually can be continued following restoration of blood pressure and volume.



Impaired Renal Function


Fosinopril sodium and hydrochlorothiazide should be used with caution in patients with severe renal disease. Thiazides may precipitate azotemia in such patients, and the effects of repeated dosing may be cumulative.


When the renin-angiotensin-aldosterone system is inhibited by ACE inhibitors, changes in renal function may be anticipated in susceptible individuals. In patients with severe congestive heart failure, whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, treatment with angiotensin-converting enzyme inhibitors (including fosinopril) may be associated with oliguria and/or progressive azotemia and (rarely) with acute renal failure and/or death.


In some studies of hypertensive patients with unilateral or bilateral renal artery stenosis, treatment with ACE inhibitors has been associated with increases in blood urea nitrogen and serum creatinine; these increases were reversible upon discontinuation of ACE inhibitor therapy, concomitant diuretic therapy, or both. When such patients are treated with fosinopril sodium and hydrochlorothiazide, renal function should be monitored during the first few weeks of therapy.


Some ACE-inhibitor-treated hypertensive patients with no apparent pre-existing renal vascular disease have developed increases in blood urea nitrogen and serum creatinine, usually minor and transient, especially when the ACE inhibitor has been given concomitantly with a diuretic. Dosage reduction of fosinopril sodium and hydrochlorothiazide may be required. Evaluation of the hypertensive patient should always include assessment of renal function (see DOSAGE AND ADMINISTRATION).



Neutropenia/Agranulocytosis


Another angiotensin-converting enzyme inhibitor, captopril, has been shown to cause agranulocytosis and bone marrow depression, rarely in uncomplicated patients (incidence probably less than once per 10,000 exposures), but more frequently (incidence possibly as great as once per 1,000 exposures) in patients with renal impairment, especially those who also have a collagen-vascular disease such as systemic lupus erythematosus or scleroderma. Available data from clinical trials of fosinopril are insufficient to show that fosinopril does not cause agranulocytosis at similar rates. Monitoring of white blood cell counts should be considered in patients with collagen-vascular disease, especially if the disease is associated with impaired renal function.


Neutropenia/agranulocytosis has also been associated with thiazide diuretics.



Fetal/Neonatal Morbidity and Mortality


ACE inhibitors can cause fetal and neonatal morbidity and death when administered to pregnant women. Several dozen cases have been reported in the world literature. When pregnancy is detected, fosinopril sodium and hydrochlorothiazide should be discontinued as soon as possible.


The use of ACE inhibitors during the second and third trimesters of pregnancy has been associated with fetal and neonatal injury, including hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death. Oligohydramnios has also been reported, presumably resulting from decreased fetal renal function; oligohydramnios in this setting has been associated with fetal limb contractures, craniofacial deformation, and hypoplastic lung development. Prematurity, intrauterine growth retardation, and patent ductus arteriosus have also been reported, although it is not clear whether these occurrences were due to the ACE-inhibitor exposure.


These adverse effects do not appear to have resulted from intrauterine ACE-inhibitor exposure that has been limited to the first trimester. Mothers whose embryos and fetuses are exposed to ACE inhibitors only during the first trimester should be so informed. Nonetheless, when patients become pregnant, physicians should make every effort to discontinue the use of fosinopril as soon as possible.


Rarely (probably less often than once in every thousand pregnancies), no alternative to ACE inhibitors will be found. In these rare cases, the mothers should be apprised of the potential hazards to their fetuses, and serial ultrasound examinations should be performed to assess the intraamniotic environment.


If oligohydramnios is observed, fosinopril should be discontinued unless it is considered life-saving for the mother. Contraction stress testing (CST), a non-stress test (NST), or biophysical profiling (BPP) may be appropriate, depending upon the week of pregnancy. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury.


Infants with histories of in utero exposure to ACE inhibitors should be closely observed for hypotension, oliguria, and hyperkalemia. If oliguria occurs, attention should be directed toward support of blood pressure and renal perfusion. Exchange transfusion or peritoneal dialysis may be required as a means of reversing hypotension and/or substituting for disordered renal function. Fosinopril is poorly dialyzed from the circulation of adults, and indeed there is no experience with any procedure for removing fosinopril from the neonatal circulation, but limited experience with other ACE inhibitors has not shown that such removal is central to the treatment of these infants.


When fosinopril is given to pregnant rats at doses about 80 to 250 times (on a mg/kg basis) the maximum recommended human dose, three similar orofacial malformations and one fetus with situs inversus were observed among the offspring. In pregnant rabbits, no teratogenic effects of fosinopril were seen in studies at doses up to 25 times (on a mg/kg basis) the maximum recommended human dose.



Impaired Hepatic Function


Rarely, ACE inhibitors have been associated with a syndrome that begins with cholestatic jaundice and progresses to fulminant hepatic necrosis and (sometimes) death. The mechanism of this syndrome is not understood. A patient receiving fosinopril sodium and hydrochlorothiazide who develops jaundice or marked elevation of hepatic enzymes should discontinue fosinopril sodium and hydrochlorothiazide tablets and receive appropriate medical follow-up.


Fosinopril sodium and hydrochlorothiazide should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma. Also, since the metabolism of fosinopril to fosinoprilat is normally dependent upon hepatic esterases, patients with impaired liver function could develop elevated plasma levels of fosinopril. In a study of patients with alcoholic or biliary cirrhosis the rate (but not the extent) of hydrolysis to fosinoprilat was reduced. In these patients the clearance of fosinoprilat was reduced, and the area under the fosinoprilat-time curve was approximately doubled.



Systemic Lupus Erythematosus


Thiazide diuretics have been reported to cause exacerbation or activation of systemic lupus erythematosus.



Precautions



General


Derangements of Serum Electrolytes

In clinical trials of fosinopril monotherapy, hyperkalemia (serum potassium at least 10% greater than the upper limit of normal) occurred in approximately 2.6% of hypertensive patients receiving fosinopril. In most cases, these were isolated values which resolved despite continued therapy. Risk factors for the development of hyperkalemia included renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes.


Conversely, treatment with thiazide diuretics has been associated with hypokalemia, hyponatremia, and hypochloremic alkalosis. These disturbances have sometimes been manifest as one or more of dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, nausea, and vomiting. Hypokalemia can also sensitize or exaggerate the response of the heart to the toxic effects of digitalis. The risk of hypokalemia is greatest in patients with cirrhosis of the liver, in patients experiencing a brisk diuresis, in patients who are receiving inadequate oral intake of electrolytes, and in patients receiving concomitant therapy with corticosteroids or ACTH.


The opposite effects of Fosinopril and Hydrochlorothiazide on serum potassium will approximately balance each other in many patients, so that no net effect upon serum potassium will be seen. In other patients, one or the other effect may be dominant. Initial and periodic determinations of serum electrolytes to detect possible electrolyte imbalance should be performed at appropriate intervals.


Chloride deficits are generally mild and require specific treatment only under extraordinary circumstances (e.g., in liver disease or renal disease). Dilutional hyponatremia may occur in edematous patients; appropriate therapy is water restriction rather than administration of salt, except in rare instances when the hyponatremia is life-threatening. In actual salt depletion, appropriate replacement is the therapy of choice.


Calcium excretion is decreased by thiazides. In a few patients on prolonged thiazide therapy, pathological changes in the parathyroid gland have been observed, with hypercalcemia and hypophosphatemia. More serious complications of hyperparathyroidism (renal lithiasis, bone resorption, and peptic ulceration) have not been seen.


Thiazides increase the urinary excretion of magnesium, and hypomagnesemia may result.


Other Metabolic Disturbances

Thiazide diuretics tend to reduce glucose tolerance and to raise serum levels of cholesterol, triglycerides, and uric acid. These effects are usually minor, but frank gout or overt diabetes may be precipitated in susceptible patients.


Cough

Presumably due to the inhibition of the degradation of endogenous bradykinin, persistent nonproductive cough has been reported with all ACE inhibitors, always resolving after discontinuation of therapy. ACE inhibitor-induced cough should be considered in the differential diagnosis of cough.


Surgery/Anesthesia

In patients undergoing surgery or during anesthesia with agents that produce hypotension, fosinopril will block the angiotensin II formation that could otherwise occur secondary to compensatory renin release. Hypotension that occurs as a result of this mechanism can be corrected by volume expansion.



Information for Patients


Angioedema

Angioedema, including laryngeal edema, can occur with treatment with ACE inhibitors, especially following the first dose. A patient receiving fosinopril sodium and hydrochlorothiazide should be told to report immediately any signs or symptoms suggesting angioedema (swelling of face, eyes, lips, or tongue, or difficulty in breathing) and to take no more drug until after consulting with the prescribing physician.


Pregnancy

Female patients of childbearing age should be told about the consequences of second and third trimester exposure to ACE inhibitors, and they should also be told that these consequences do not appear to have resulted from intrauterine ACE inhibitor exposure that has been limited to the first trimester. These patients should be asked to report pregnancies to their physicians as soon as possible.


Symptomatic Hypotension

A patient receiving fosinopril sodium and hydrochlorothiazide tablets should be cautioned that lightheadedness can occur, especially during the first days of therapy, and that it should be reported to the prescribing physician. The patients should be told that if syncope occurs, fosinopril sodium and hydrochlorothiazide should be discontinued until the physician has been consulted.


All patients should be cautioned that inadequate fluid intake, excessive perspiration, diarrhea, or vomiting can lead to an excessive fall in blood pressure, with the same consequences of lightheadedness and possible syncope.


Hyperkalemia

A patient receiving fosinopril sodium and hydrochlorothiazide should be told not to use potassium supplements or salt substitutes containing potassium without consulting the prescribing physician.


Neutropenia

Patients should be told to promptly report any indication of infection (e.g., sore throat, fever), which could be a sign of neutropenia.



Laboratory Tests


Therapy with fosinopril sodium and hydrochlorothiazide should be interrupted for a few days before carrying out tests of parathyroid function.


Fosinopril may cause false low measurement of serum digoxin levels when the Digi-Tab® (Nuclear Medical) RIA Kit is used. The accuracy of the Coat-A-Count® (Diagnostic Products Corporation) kit is not affected.



Drug Interactions


Potassium Supplements and Potassium-Sparing Diuretics

As noted above ("Derangements of Serum Electrolytes"), the net effect of fosinopril sodium and hydrochlorothiazide may be to elevate a patient's serum potassium, to reduce it, or to leave it unchanged. Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia. If concomitant use of such agents is indicated, they should be given with caution, and the patient's serum potassium should be monitored frequently.


Lithium

Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. Because renal clearance of lithium is reduced by thiazides, the risk of lithium toxicity is presumably raised further when, as in therapy with fosinopril sodium and hydrochlorothiazide tablets, a thiazide diuretic is co-administered with the ACE inhibitor. Fosinopril sodium-hydrochlorothiazide and lithium should be coadministered with caution, and frequent monitoring of serum lithium levels is recommended.


Antacids

In a clinical pharmacology study, serum levels and urinary excretion of fosinoprilat were reduced when fosinopril was co-administered with an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) suggesting that antacids may impair absorption of fosinopril. If concomitant administration of these agents is indicated, dosing should be separated by 2 hours.


Gold

Nitritoid reactions (symptoms include facial flushing, nausea, vomiting, and hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including fosinopril sodium and hydrochlorothiazide.


Other

The bioavailability of unbound fosinoprilat is not altered by coadministration of fosinopril with aspirin, chlorthalidone, cimetidine, digoxin, metoclopramide, nifedipine, propranolol, propantheline, or warfarin. Other ACE inhibitors have had less than additive effects with beta- adrenergic blockers, presumably because drugs of both classes lower blood pressure by inhibiting parts of the renin-angiotensin system.


Interaction studies with warfarin have failed to identify any clinically important effects of fosinopril on the serum concentration or clinical effects of the anticoagulant.


Insulin requirements in diabetic patients may be increased, decreased, or unchanged.


Thiazides may decrease arterial responsiveness to norepinephrine, but not enough to preclude effectiveness of the pressor agent for therapeutic use.


Thiazides may increase the responsiveness to tubocurarine.


The diuretic, natriuretic, and antihypertensive effects of thiazide diuretics may be reduced by concurrent administration of nonsteroidal anti-inflammatory agents; the effects (if any) of these agents on the antihypertensive effect of fosinopril sodium and hydrochlorothiazide have not been studied.


By alkalinizing the urine, hydrochlorothiazide may decrease the effectiveness of methenamine.


Cholestyramine and Colestipol Resins

Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins. Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively.



Carcinogenesis, Mutagenesis, Impairment of Fertility


Fosinopril and Hydrochlorothiazide

Reproductive studies and long-term carcinogenicity studies with fosinopril sodium and hydrochlorothiazide has not been conducted. The combination of Fosinopril and Hydrochlorothiazide was not mutagenic in the Ames microbial mutagen test, the mouse lymphoma forward mutation assay, or the Chinese hamster ovary cell cytogenetic assay. The combination was also not genotoxic in a mouse micronucleus test in vivo.


Fosinopril Sodium

No evidence of a carcinogenicity was found when fosinopril was given in the diet to rats and mice for up to 24 months at doses up to 400 mg/kg/day. On a body-weight basis, the highest dose was about 250 times the maximum human dose of 80 mg, given to a 50 kg subject. On a body-surface-area basis, this dose is 20 (mice) to 40 (rats) times the maximum human dose.


Neither fosinopril nor the fosinoprilat moiety was mutagenic in the Ames microbial mutagen test, the mouse lymphoma forward mutation assay, or a mitotic gene conversion assay. Fosinopril was also not genotoxic in a mouse micronucleus test in vivo and a mouse bone marrow cytogenetic assay in vivo.


In Chinese hamster ovary cell cytogenetic assay, fosinopril increased the frequency of chromosomal aberrations when tested without metabolic activation at a concentration that was toxic to the cells. However, there was no increase in chromosomal aberrations at lower drug concentrations without metabolic activation or at any concentration with metabolic activation.


There were no adverse reproductive effects in male and female rats treated with up to 60 mg/kg daily. At doses 4 times higher, slight increases in pairing time were seen. This higher dose is about 125 (body-surface-area basis) or 600 (body-weight basis) times greater than the dose received by a 50 kg human receiving 20 mg a day.


Hydrochlorothiazide

Under the auspices of the National Toxicology Program, rats and mice received hydrochlorothiazide for two years at doses up to 100 (rats) and 600 (mice) mg/kg/day. On a body weight basis, these highest doses were about 2400 times (mice) or 400 times (rats) the fosinopril sodium and hydrochlorothiazide dose of 12.5 mg, given to a 50 kg subject. On a body surface area basis, these doses are 226 times (mice) and 82 times (rats) the fosinopril sodium-hydrochlorothiazide dose. These studies uncovered no evidence of carcinogenicity in rats or female mice, but there was equivocal evidence of hepatocarcinogenicity in male mice.


Hydrochlorothiazide was not genotoxic in in vitro assays using strains TA 98, TA 100, TA 1535,TA 1537, and TA 1538 of Salmonella typhimurium (Ames assay); in the Chinese Hamster Ovary (CHO) test for chromosomal aberrations; or in in vivo assays using mouse germinal cell chromosomes; Chinese Hamster bone-marrow chromosomes, and the Drosophila sex-linked recessive lethal trait gene. Using concentrations of hydrochlorothiazide of 43 mg/mL to 1300 mg/mL, positive test results were obtained in the in vitro CHO Sister Chromatid Exchange (clastogenicity) test and in the Mouse Lymphoma Cell (mutagenicity) assays. Using an unspecified concentration of hydrochlorothiazide, positive test results were also obtained in the Aspergillus nidulans nondisjunction assay.


No adverse effects upon fertility were seen when rats and mice received dietary hydrochlorothiazide prior to mating and throughout gestation at doses up to 4 (rats) and 100 (mice) mg/kg/day. These doses are from 3.2 (body surface area basis in rats) to 400 (weight basis in mice) times greater than the dose received by a 50 kg human receiving 12.5 mg a day.



Pregnancy


Pregnancy Categories C (first trimester) and D (second and third trimesters). See WARNINGS, Fetal/Neonatal Morbidity and Mortality.



Nursing Mothers


Both Fosinopril and Hydrochlorothiazide are excreted in human milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue fosinopril sodium-hydrochlorothiazide, taking into account the importance of the drug to the mother.



Geriatric Use


Clinical studies of fosinopril sodium/hydrochlorothiazide did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.



Pediatric Use


Safety and effectiveness in pediatric patients have not been established.



Adverse Reactions


Fosinopril sodium and hydrochlorothiazide tablets have been evaluated for safety in over 660 patients with hypertension; approximately 137 of these patients were treated for more than one year. The observed adverse events were generally mild, transient, and similar to those seen with Fosinopril and Hydrochlorothiazide taken separately. There was no relationship between the incidence of side effects and age.


In placebo-controlled clinical trials of fosinopril sodium and hydrochlorothiazide, the usual duration of therapy was two months. Adverse clinical or laboratory events led to discontinuation of therapy by 4.3% of 368 placebo-treated patients and by 3.5% of 660 fosinopril sodium and hydrochlorothiazide treated patients.


The most common reasons for discontinuation of therapy with fosinopril sodium-hydrochlorothiazide in U.S. studies were headache (0.3%), cough (0.3%; see PRECAUTIONS), and fatigue (0.2%).


The side effects considered probably or possibly related to study drug that occurred in placebo-controlled trials in more than 2% of patients treated with fosinopril sodium and hydrochlorothiazide is shown in the table below.

























Reactions Possibly or Probably Drug-Related (Incidence in Placebo-Controlled Studies)

Fosinopril Sodium and


Hydrochlorothiazide


(N=660)


%

Placebo


(N=368)


%
Headache7.012.8
Cough5.61.1
Fatigue3.92.4
Dizziness3.22.2
Upper Respiratory Infection2.32.7
Musculoskeletal Pain2.01.9

Other side effects considered possibly or probably related to study drug that occurred in controlled trials in 0.5% to <2.0% of patients treated with fosinopril sodium and hydrochlorothiazide, and rarer but clinically significant events regardless of causal relationship were:


General: Chest pain, weakness, fever, viral infection.


Cardiovascular:Orthostatic hypotension (seen in 1.8% of fosinopril sodium and hydrochlorothiazide patients and 0.3% of placebo patients; no patients discontinued therapy due to orthostatic hypotension), edema, flushing, rhythm disturbance, syncope.


Dermatologic: Pruritus, rash.


Endocrine/Metabolic: Sexual dysfunction, change in libido, breast mass.


Gastrointestinal: Nausea/vomiting, diarrhea, dyspepsia/heartburn, abdominal pain, gastritis/ esophagitis.


Immunologic: Angioedema (see WARNINGS: Head and Neck Angioedemaand Intestinal Angioedema).


Musculoskeletal: Myalgia/muscle cramps.


Neurologic/Psychiatric:Somnolence, depression, numbness/paresthesia.


Respiratory: Sinus congestion, pharyngitis, rhinitis.


Special Senses: Tinnitus.


Urogenital: Urinary tract infection, urinary frequency, dysuria.


Laboratory Test Abnormalities: Serum electrolytes, uric acid, glucose, magnesium, cholesterol, triglycerides, and calcium (see PRECAUTIONS). Neutropenia.



Fetal/Neonatal Morbidity and Mortality


See WARNINGS, Fetal/Neonatal Morbidity and Mortality


Antihypertensive monotherapy with fosinopril has been evaluated for safety in more than 1500 patients, of whom approximately 450 patients were treated for a year or more. The observed adverse events included events similar to those seen with fosinopril sodium and hydrochlorothiazide; in addition, the following others have also been reported with fosinopril:


Cardiovascular: Angina, myocardial infarction, cere